Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer

Ginsberg, Robert J.; Rubinstein, Larry

doi:10.1016/0003-4975(95)00537-u

Cited by 2,611 publications

(1,483 citation statements)

References 27 publications

Supporting

Mentioning

1,368

Contrasting

Unclassified

Order By: Relevance

“…In the patients who underwent rigorous follow-up detection of SPC was assured. Three primary lung cancers were detected during routine follow-up and The studies using the person-years method to calculate the incidences of SPC showed a range from 1.7 to 4.3 per 100 patientyears (Thomas and Rubinstein, 1993;Ginsberg and Rubinstein, 1995;Martini et al, 1995;Jeremic et al, 2001;Kawaguchi et al, 2006). In the present studies, the rate of SPC was 2.4 per 100 patient-years, in agreement with previous findings.…”

Section: Discussionsupporting

confidence: 90%

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Limited resection may increase the risk of relapse and mortality in lung cancer patients [82]. However, when it is the only possible treatment option, limited resection is recommended compared to omit surgery.…”

Section: Discussion Of Main Resultsmentioning

confidence: 99%

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease

Bugge

Lund

Brunborg

et al. 2016

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

“…This statement has been re-emphasised recently by a panel of experts from the American College of Chest Physicians and the STS [16]. Lobectomy versus segmentectomy In a landmark paper, Ginsberg and the Lung Cancer Study Group showed that lobectomy should be preferred to wedge resection or segmentectomy whenever possible, as it resulted in a much lower local recurrence rate and better cancer-free survival [58]. Recent publications suggest that this view may have to be revised in patients with small peripheral tumours and no hilar lymph node involvement.…”

Section: Surgery For Early Stage Lung Cancer (Stage I and Ii)mentioning

confidence: 99%

Surgery for nonsmall cell lung cancer

Lang-Lazdunski

2013

European Respiratory Review

View full text Add to dashboard Cite

Surgery remains the best curative option in patients with early stage lung cancer (stage I and II). Developments in minimally invasive techniques now allow surgeons to perform lung resections on elderly patients, patients with poor pulmonary function or significant cardiopulmonary comorbidities. New techniques, such as stereotactic radiotherapy and ablative procedures, are being evaluated in early-stage lung cancer and may represent an alternative to surgery in patients unfit for lung resection. Perioperative mortality rates have dropped significantly at most institutions in the past two decades and complications are managed more efficiently. Progress in imaging and staging techniques have helped cut futile thoracotomy rates and offer patients the most adequate treatment options. Large randomised trials have helped clarify the role of neoadjuvant, induction and adjuvant chemotherapy, as well as radiotherapy. Surgery remains an essential step in the multimodality therapy of selected patients with advanced-stage lung cancer (stage III and IV). Interventional and endoscopic techniques have reduced the role of surgery in the diagnosis and staging of nonsmall cell lung cancer, but surgery remains an important tool in the palliation of advanced-stage lung cancer. Large national/international surgical databases have been developed and predictive risk-models for surgical mortality/morbidity published by learned surgical societies. Nonetheless, lung cancer overall survival rates remain deceptively low and it is hoped that early detection/screening, better understanding of tumour biology and development of biomarkers, and development of efficient targeted therapies will help improve the prognosis of lung cancer patients in the next decade. @ERSpublications Despite progress in surgical techniques, radiotherapy techniques and targeted therapy, lung cancer prognosis remains poor

show abstract

Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer

Cited by 2,611 publications

References 27 publications

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease

Surgery for nonsmall cell lung cancer

Contact Info

Product

Resources

About